Sunday, February 9, 2025

Moderna and Mitsubishi Tanabe Partner to Promote mRNA Vaccines in Japan

Similar articles

Moderna, Inc. and Mitsubishi Tanabe Pharma Corporation announced a joint agreement for the co-promotion of Moderna’s mRNA respiratory vaccine portfolio in Japan, including its COVID-19 vaccine, Spikevax®. This strategic partnership aims to enhance the accessibility and impact of Moderna’s innovative vaccines on public health in Japan. Under this agreement, Moderna will manage the manufacturing, sales, medical education, and distribution of its mRNA respiratory vaccines.

Both companies will work together to ensure broad access to these vaccines, maximizing their public health impact. The agreement has an initial term until March 31, 2029. Financial terms of the deal remain undisclosed. Kazumasa Nagayama, President and Representative Director of Moderna Japan, expressed enthusiasm about the partnership, highlighting Mitsubishi Tanabe Pharma’s significant heritage and experience in Japan. He emphasized the ongoing threat posed by COVID-19 and the importance of providing effective vaccines.

Subscribe Weekly Market Access News

* indicates required

Moderna’s mRNA Technology to Revolutionize Disease Treatment and Prevention

Akihiro Tsujimura, Representative Director of Mitsubishi Tanabe Pharma, also welcomed the collaboration. He acknowledged Moderna’s global impact during the COVID-19 pandemic and expressed commitment to contributing to public health in Japan through their vaccine business. Moderna is a pioneer in mRNA medicine, transforming the development and manufacturing of medicines. By advancing mRNA technology, Moderna has revolutionized treatment and prevention of diseases, including producing one of the earliest and most effective COVID-19 vaccines.

The company’s mRNA platform has enabled the creation of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by the values and mindsets of Moderna, the company aims to deliver significant health impacts through mRNA medicines.

 mRNA

Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma Corporation (MTPC) is the pharmaceutical arm of Mitsubishi Chemical Group (MCG) and one of the oldest pharmaceutical companies in the world, founded in 1678. Headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry, MTPC focuses on ethical pharmaceuticals. MCG has prioritized healthcare in its management policy, “Forging the Future”.

MTPC’s mission is “Creating hope for all facing illness”, focusing on central nervous system, immuno-inflammation, diabetes, kidney diseases, and cancer. The company emphasizes “precision medicine” to provide highly satisfactory treatments by identifying patient populations with high potential for efficacy and safety. Additionally, MTPC develops “around the pill solutions” to address specific patient concerns, including disease prevention, pre-symptomatic care, aggravation prevention, and prognosis improvement. More information about MTPC can be found on their website.

 

Resource: Moderna, July 08, 2024

You can follow our news on our Telegram, LinkedIn and Youtube accounts.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article